Acute Cerebral InfarctionNCT07513428
Correlation Analysis Between Peripheral Blood PrPC Levels and Disease Severity and Prognosis in Patients With Acute Cerebral Infarction
An observational study of Acute Cerebral Infarction, run by The First Hospital of Jilin University at 1 site in China.
Trial summary
The primary objective of this observational study is to investigate alterations in PrPc levels in peripheral blood during acute cerebral infarction, as well as the correlation between these changes and both disease severity and prognosis. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Acute Cerebral Infarction
- How many people
- 79 participants
- Where
- 1 siteChina
- Study dates
- 6 Jun 2023to 1 Sep 2024
- How long will I take part?
- 90 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years were consecutively enrolled in this study. For wake-up strokes, onset was defined as last known well. Anterior circulation ischemic stroke patients were defined by infarct location within the ICA-MCA and/or ACA territories on MRI-DWI (supported by CTA/MRA when available).
Who may be able to join
- patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years
Who cannot join
- (1) patients who received intravenous thrombolysis or endovascular intervention; (2) patients with infectious diseases, autoimmune diseases, or those receiving immunosuppressive or immunomodulatory therapy; (3) patients with a history of cerebral infarction or intracerebral hemorrhage within the past year; (4) patients with severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal, serum creatinine levels >265 μmol/L, heart failure, or malignant tumors.
Trial locations and contacts
1 site in 1 country.
About this study
The primary objective of this observational study is to investigate alterations in PrPc levels in peripheral blood during acute cerebral infarction, as well as the correlation between these changes and both disease severity and prognosis. Additionally, it aims to explore the association between peripheral blood PrPc and T-cell-mediated inflammatory responses in acute cerebral infarction. Key research questions addressed include: how PrPc concentrations in peripheral blood change during acute cerebral infarction, and whether such variations correlate with clinical severity and patient outcomes. No interventions were administered in this study, and all patients received standard diagnostic and therapeutic care without disruption. Fasting venous blood samples were collected on the morning following hospital admission, and follow-up assessments using the modified Rankin Scale (mRS) were conducted at 90 days post-onset.
- Conditions
- Acute Cerebral Infarction
- Keywords
- acute cerebral infarction, the cellular prion protein, CD4+T cells
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| mild stroke | admission NIHSS score ≤ 6 | |
| moderate-to-severe stroke | admission NIHSS score > 6 | |
| control | Volunteers from the health examination center were recruited as controls |
What is being measured
The primary outcome is the main question the study is designed to answer.
3-month mRS
Functional outcomes were assessed at 3 months by trained medical personnel via telephone interviews using the modified Rankin Scale (mRS). Favorable outcomes were defined as no symptoms to mild disability (mRS 0-2), whereas unfavorable outcomes were defined as moderate disability to death (mRS 3-6).
Measured: three months after the onset of the disease
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2026
- Study start6 Jun 2023
- Primary completion3 Jun 2024
- Study completion1 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Cerebral InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 79 participants (actual)
- Target duration
- 90 Days
Sponsor and investigators
- Lead sponsor
- The First Hospital of Jilin University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07513428
- Sponsor's protocol ID
- 23K099-001
- Status last verified
- Mar 2026
- First submitted
- 31 Mar 2026
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The paper has not yet been published and is therefore not available for public disclosure at present.
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation Analysis Between Peripheral Blood PrPC Levels and Disease Severity and Prognosis in Patients With Acute Cerebral Infarction
- ClinicalTrials.gov ID
- NCT07513428
- Acronym / sponsor ID
- 23K099-001
- Conditions
- Acute Cerebral Infarction
- Keywords
- acute cerebral infarction, the cellular prion protein, CD4+T cells
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 79 participants (actual)
- Lead sponsor
- The First Hospital of Jilin UniversityUniversity, hospital or other
- Study start
- 6 Jun 2023 (actual)
- Primary completion
- 3 Jun 2024 (actual)
- Study completion
- 1 Sep 2024 (actual)
- First posted
- 7 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this observational study is to investigate alterations in PrPc levels in peripheral blood during acute cerebral infarction, as well as the correlation between these changes and both disease severity and prognosis. Additionally, it aims to explore the association between peripheral blood PrPc and T-cell-mediated inflammatory responses in acute cerebral infarction. Key research questions addressed include: how PrPc concentrations in peripheral blood change during acute cerebral infarction, and whether such variations correlate with clinical severity and patient outcomes. No interventions were administered in this study, and all patients received standard diagnostic and therapeutic care without disruption. Fasting venous blood samples were collected on the morning following hospital admission, and follow-up assessments using the modified Rankin Scale (mRS) were conducted at 90 days post-onset.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 90 Days
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| mild stroke | – | –admission NIHSS score ≤ 6 |
| moderate-to-severe stroke | – | –admission NIHSS score > 6 |
| control | – | –Volunteers from the health examination center were recruited as controls |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years were consecutively enrolled in this study. For wake-up strokes, onset was defined as last known well. Anterior circulation ischemic stroke patients were defined by infarct location within the ICA-MCA and/or ACA territories on MRI-DWI (supported by CTA/MRA when available).
Key inclusion criteria (1 listed)
- patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years
Key exclusion criteria (1 listed)
- (1) patients who received intravenous thrombolysis or endovascular intervention; (2) patients with infectious diseases, autoimmune diseases, or those receiving immunosuppressive or immunomodulatory therapy; (3) patients with a history of cerebral infarction or intracerebral hemorrhage within the past year; (4) patients with severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal, serum creatinine levels >265 μmol/L, heart failure, or malignant tumors.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
3-month mRS
Time frame: three months after the onset of the disease
Functional outcomes were assessed at 3 months by trained medical personnel via telephone interviews using the modified Rankin Scale (mRS). Favorable outcomes were defined as no symptoms to mild disability (mRS 0-2), whereas unfavorable outcomes were defined as moderate disability to death (mRS 3-6).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Individual participant dataSharing planned: No. The paper has not yet been published and is therefore not available for public disclosure at present.
Related trials for Acute Cerebral Infarction
RecruitingPhase 3
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
Acute Ischemic Stroke, Large Vessel Occlusion
RecruitingPhase 4
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
Stroke, Stroke, Acute Ischemic
Not yet recruitingObservational study
Cardiovascular Risk in Patients With IBD
Ulcerative Colitis (UC), Crohn's Diseases
Recruiting
Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)
Stroke, Acute, Stroke
Not yet recruitingPhase 2/3
Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Cerebral Infarction, run by The First Hospital of Jilin University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
3-month mRS (time frame: three months after the onset of the disease). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.